World Intranasal Drug Delivery Market

http://www.reportlinker.com/p092577/World-Intranasal-Drug-Delivery-Market.html

This report analyzes the US market for Intranasal Drug Delivery in US$ Million. The product is analyzed by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual forecasts are provided for the period of 2000 through 2015. The report profiles 78 companies including many key and niche players such as Aegis Therapeutics LLC, Alza Corporation, AptarGroup, Inc., Archimedes Pharma, AstraZeneca Plc, MedImmune, Inc., Bayer Consumer Care, Bespak Plc, GlaxoSmithKline Plc, Intranasal Therapeutics, Inc., Javelin Pharmaceuticals, Inc., Kurve Technology, Inc., Nastech Pharmaceutical Company, Inc., Novartis AG, OptiNose AS, Pfizer, Inc., Rexam Plc, Schering-Plough Corporation, Sanofi-Aventis S.A., and Unigene Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

INTRANASAL DRUG DELIVERY MCP-1795A US MARKET REPORTCONTENTSI. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-2Product Definitions And Scope of Study I-3II. A US MARKET REPORT1. Industry Overview II-1Drug Delivery: A Quick Primer II-1The Nose: An Attractive Avenue to Cross the Blood Brain Barrier II-1Self-Administration of Drugs Brings Intranasal Drug DeliveryInto the Spotlight II-2Research & Technology Opens Up New Therapeutic Areas forNasal Drug Delivery II-2Recent Product Developments in the US Intranasal DrugDelivery Market (2007) II-2Table 1: The US Nasal Drug Delivery Market: Sales Of Top SixNasal Formulations for The Year 2005 (In US$ Million)(includes corresponding Graph/Chart) II-3R&D: Critical to the Commercialization of Intranasal DrugDelivery II-3Tight Junction Biology: A Key Speed Breaker inCommercialization II-3RNA Interference (RNAi): A Tool To Manipulate Tight Junctions II-4Why Is Nasal Drug Delivery the Theme of All Drug DeliveryResearch Projects? II-4Nasal Drug Delivery Devices & Equipments II-4Preservative Free Systems (P.F.S.) II-4Traditional Vs Advanced Intranasal Drug Delivery Devices II-6Pitfalls Of Traditional Delivery Devices II-6The Promise of New Advanced Delivery Devices II-6Bi-Directional Nasal Drug Delivery: A Technology With aHuge Potential II-6Benefits of Bi-Directional Delivery Authenticated ThroughResearch Studies II-7Market for Nasal Spray Devices in the US II-7GSK Wields the Leadership Scepter in the US Intranasal DrugsMarket II-8The Batting Order II-8Table 2: US Market for Intranasal Drug Delivery(2004-2006): Percentage Market Share Breakdown of LeadingPlayers - GlaxoSmithKline, Schering-Plough, AstraZeneca,Sanofi-Aventis, and Others (includes correspondingGraph/Chart) II-82. Market Dynamics II-9Innovation in Drug Delivery: A Talisman For Success II-9Controlled Release Technology Is the Buzz Word II-9Target-Specific Delivery Devices: Of Critical Value II-9Safety and Cost: Primary Growth Drivers II-9Preservatives Losing Sheen in Nasal Spray Formulations II-10Multi-Dose Containers Evolve to Offer Resistance AgainstMicrobial Contamination II-10Bioavailability: An Important Facet of Intranasal Drug Delivery II-10Chemical Modification II-10Transient Modification & Limited Enzymatic Activity II-11Bioavailability of Large Molecules II-11Bio-Adhesive Polymers: Useful in Increasing Drug Absorption II-11Mixed Opinions on Efficiency of Calcitonin Nasal Spray II-11Nasal Preparations Gaining Foothold in Cough and AllergicCategories II-11Patent Expiries Impact Market Opportunities II-123. Technology Overview II-13Intranasal Drug Delivery: A Descriptive Exposition II-13Nasal Physiology II-13Challenges Involved In Formulating Nasal Drugs II-14The Importance of Bioadhesion II-15Challenges Involved In Designing Devices II-15Overview on the Traditional Drug Administration Routes,Molecular Weight Capabilities, and Dosage Range II-15Intranasal Drugs - Prescription (Rx) and Over-the- Counter (OTC) II-16Differences Between Systemic Delivery and Local Effects II-16Nasal Powders Vs Sprays II-16Nasal Drug Delivery Devices II-17Types of Drug Delivery Devices II-17Droppers II-17Sprays II-17Aerosol Containers/Inhalers II-17Pumps II-18Nasal Aspirator II-18Intranasal Drug Delivery Vis-a-vis Other Delivery Techniques II-18Table 3: US Market for Intranasal Drugs: Percentage share ofTopical and Systemic Drugs by value for the Years 2006 and2012 II-18Limitations of Intranasal Drug Delivery II-19Allergy II-19Definition II-19Symptoms II-19Allergic Rhinitis II-20Nasal Allergies II-20Table 4: US Market for Nasal Sprays, Drops and Inhalers: Top10 Brands Ranked by Dollar Sales Through Drug Stores for theYear Ended January 2008 (In US $ Million) (includescorresponding Graph/Chart) II-20Table 5: US Market for Nasal Sprays, Drops and Inhalers: Top10 Brands Ranked by Unit Sales Through Drug Stores for theYear Ended January 2008 (In Thousand Units) (includescorresponding Graph/Chart) II-21Table 6: US Market for Nasal Sprays: Top Five Nasal Spraysfor Cough, Cold, Sinus and Allergy Ranked by Dollar RetailSales for the Year Ended January 2008 (In US $ Million)(includes corresponding Graph/Chart) II-214. Nasal Drugs: An Overview II-22Nasal Drugs For Allergies II-22Corticosteroid Nasal Sprays II-22Flonase II-22Patanase II-22Beconase II-22Other Nasal Corticosteroid Drugs II-23Antihistamine Nasal Sprays II-23Astelin Nasal Spray II-23Otrivin Nasal Spray II-23Livostin Nasal Spray II-23Other Nasal Antihistamine Drugs II-23Other Brands of Allergy Relievers II-24Nasal Drugs for Postmenopausal Osteoporosis II-24Calcitonin-Salmon Nasal Spray II-24Miacalcin Nasal Spray II-24Fortical® Nasal Spray II-24Intranasal Pain Management Drugs II-24Stadol Nasal Spray II-25Rylomine II-25Imitrex II-25Migranal II-26Zolmitriptan Nasal Spray II-26Intranasal Analgesics For Treating Migraine II-26Select Intranasal Pain Management Products in Development II-26Intranasal Vaccination II-27Process of Intranasal Immunization II-27Market Drivers II-28"LAIV" Nasal Spray Flu Vaccine II-28FluMist® Vaccine From MedImmune II-28Intranasal Drugs for Sexual Dysfunction II-29Table 7: US Market for Intranasal Drugs: Projected Revenuesfor Intranasal Sexual Dysfunction Drugs for the Years 2010through 2012 in US$ Million (includes correspondingGraph/Chart) II-29Nasal Spray for Treating Vitamin B12 Deficiency II-30Nasal Spray for Aiding Smoking Cessation II-30Intranasal Drugs In the Pipeline II-305. Research & Development II-31Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36Nasal Spray II-31Archimedes Pharma Commences Phase III Trials for NasalFent® II-31Archimedes Presents New Clinical Data on NasalFent® II-31LigoCyte Commences Clinical Trials for Intranasal NorovirusVaccine II-31Javelin Pharmaceuticals Reveals Phase 2 Study Results forPMI-100/150 II-31Javelin Pharmaceuticals Commences Phase III Studies for PMI-150 II-32Nastech Commences Phase 2 Trials for Insulin Nasal Spray II-32ACAAI Reveals Results for Trials of Nasacort® AQ Nasal Sprayin Children II-32TGAR01H from Fabre Kramer II-33Aegis Therapeutics Completes First Human Clinical Study onIntravail® II-33Nastech Pharmaceutical Presents Clinical Test Results onParathyroid Hormone II-33Zolmitriptan Promises Relief for Cluster Headaches II-33CAIV-T: More Effective than Injectable Influenza Vaccines II-34Intranasal Therapeutics Conducts Study on Midazolam II-34Nastech Announces Phase I Results of Insulin Nasal Spray II-34Archimedes Completes Phase II Trials of NASALFENT II-35Intranasal Corticosteroid Proven Effective for TreatingAllergic Rhinitis II-35Aegis Files DMF for Intravail II-35Nasal Sprays: A New-Generation Treatment for GynecologicalProblems II-35Aegis Therapeutics Conducts Feasibility Study on Drug DeliveryTechnology II-36GelVac Powder Delivery System Completes Phase I Clinical Trial II-36DelSite Files DMF with the FDA II-37OptiNose Develops Intranasal Delivery System for Osteoporosis II-37Nastech Initiates Dose Ranging Study of PYY(3-36) II-37Valois Develops New Nasal Dispensing System II-37Rigel Pharmaceuticals to Initiate R112 Phase II Clinical Trial II-38MedPointe Pharmaceuticals Demonstrates ACT1 Study Results onASTELIN® II-38Bentley Pharmaceuticals Demonstrates Clinical Trial Results ofits Intra Nasal Insulin Spray II-386. Recent Technological Developments II-39New-Generation Technologies and Devices II-39ViaNase from Kurve Technology II-39A New Product from OptiNose II-39Nastech's "Tight Junction Biology" Research Program II-40ChiSys(TM) Nasal Delivery Technology from Archimedes II-407. Product Innovations/Introductions II-41Aegis Therapeutics Develops ProTek(TM) II-41Heel Launches Luffeel® in the US II-41Palatin Technologies to Develop Bremelanotide II-41Archimedes to Introduce Intranasal Formulation of Human GrowthHormone II-41Sinofresh Launches SinoFresh(TM) Nasal & Sinus Care II-41PARI Respiratory Launches Nasal Drug Delivery Program II-42OptiNose to Develop New Range of Intranasal Products II-42OptiNose and Cambridge Consultants to Develop Advanced NasalDelivery Device II-42Kurve Technology Develops ViaNase ID(TM) II-42Upsher-Smith Introduces Fortical® Nasal Spray II-43Schering-Plough Launches New Formulation of NASONEX® II-43AstraZeneca Unveils Rhinocort Aqua in the US II-438. Recent Industry Activity II-44Zelos Therapeutics Collaborates with Aegis Therapeutics II-44ImmuneRegen BioSciences Partners with LRRI II-44Avamys(TM) Nasal Spray Receives Approval in Europe II-44PMI-150 Receives Canadian Patent II-44USFDA Approves FluMist® for Young Children II-45USFDA Approves Veramyst Nasal Spray for Individuals Aged TwoYears and Above II-45Kurve Technology Inks Agreement with Schering-Plough II-45MedImmune Clarifies FDA Observations II-45FluMist® Receives FDA Approval for Refrigerated Formulation II-45Nastech Regains Rights for PTH1-34 Nasal Spray II-45NASONEX® Receives Ease-of-Use Commendation from ArthritisFoundation II-46Aegis Therapeutics Establishes Cedar Therapeutics Inc. II-46EMEA Provides Encouraging Feedback for Avamys(TM) Nasal Spray II-46Kurve Technologies Introduces Blog on Nasal Drug Delivery II-46Accentia Extends Agreement with Mayo Foundation II-46Nastech Signs Development and License Agreement with Amylin II-47MedImmune's FluMist Plant Gets FDA Approval II-47ShinNippon Subsidiaries Sign Licensing Agreement with TokaiPharmaceuticals II-47MeadWestvaco Acquires Saint-Gobain Calmar II-47Merck Terminates PYY3-36 Partnership with Nastech II-47Inspire Signs Licensing Agreement with Boehringer Ingelheim II-48P&G Partners with Nastech to Develop PTH(1-34) II-48Unigene Laboratories Signs Distribution Agreement with TzamalBio Pharma II-49GlaxoSmithKline Seeks Marketing Approval for FluticasoneFuroate in the US and Europe II-49Kurve Technology Relocates Corporate Headquarters II-49Kurve Inks an Agreement with DARA BioSciences II-49Kurve Enters into a Development Agreement with Schering-Plough II-49Altana Submits NDS for Approval of Ciclesonide Nasal Spray inCanada II-49Altana Pharma AG Receives FDA Approval for Pediatric Use ofOmnaris II-50Intranasal Therapeutics Inc. Receives Financial Funding II-50FDA Completes Pre-Approval Inspections at Nastech's WashingtonFacility II-50Kos Signs Exclusive License Agreement with SkyePharma II-50Bentley Signs Agreement with Biocon II-50MedImmune Files New Drug Application with the FDA II-51Intranasal Therapeutics Files Patent Application for SyntheticTHC II-51Ionix Pharmaceuticals in Collaboration with Reckitt Benckiserfor Drug Development II-51University of Kentucky Receives Patent for new Intranasal Device II-51Intranasal Technology Extends Collaboration with AegisTherapeutics II-52Accentia Biopharmaceuticals Signs License Agreement withCollegium Pharmaceuticals II-52Aegis Therapeutics Extends License Agreement with IntranasalTechnologies II-52Bentley Pharmaceuticals Signs Agreement with Dong SungPharmaceuticals II-52Unigene Gets FDA Approval for Fortical Calcitonin- SalmonNasal Spray II-53OptiNose Signs Collaborative Agreement with MedPharm II-53West Pharmaceutical Divests Drug Delivery Business toArchimedes Pharma II-53Nastech Pharmaceutical Receives FDA Approval for NascobalNasal Spray II-53Par and Nastech Sign Licensing Agreement II-53Aegis Therapeutics Signs Licensing Agreement with Universityof Alabama II-54ITI Receives a Patent for Sedation Inducing Nasal Drug II-54Inyx Bags Order from Australian OTC Drug Company II-549. Focus on Select Global Players II-55Aegis Therapeutics LLC (USA) II-55Alza Corporation (USA) II-55AptarGroup, Inc. (USA) II-55Archimedes Pharma Limited. (UK) II-56AstraZeneca Plc (UK) II-56MedImmune, Inc. (USA) II-56Bayer Consumer Care (USA) II-57Bespak Plc (UK) II-57GlaxoSmithKline Plc (UK) II-57Intranasal Therapeutics, Inc. (USA) II-58Javelin Pharmaceuticals, Inc (USA) II-58Kurve Technology, Inc. (USA) II-58Nastech Pharmaceutical Company, Inc. (USA) II-58Novartis AG (Switzerland) II-59OptiNose AS (Norway) II-59Pfizer, Inc. (USA) II-59Rexam Plc (UK) II-60Schering-Plough Corporation (USA) II-60Sanofi-Aventis S.A. (France) II-60Unigene Laboratories, Inc. (USA) II-6010. Market Analytics II-61Table 8: US Recent Past, Current & Future Analysis forIntranasal Drug Delivery by Therapeutic Area - AllergicInfections, Analgesics, Osteoporosis, and Vaccinations MarketsIndependently Analyzed by Annual Sales Figures in US$ Millionfor Years 2000 through 2010 II-61Table 9: US Long-term Projections for Intranasal DrugDelivery by Therapeutic Area - Allergic Infections,Analgesics, Osteoporosis, and Vaccinations MarketsIndependently Analyzed by Annual Sales Figures in US$ Millionfor Years 2011 through 2015 (includes correspondingGraph/Chart) II-61Table 10: US 10-Year Perspective for Intranasal Drug Deliveryby Therapeutic Area -Percentage Breakdown of Values Sales forAllergic Infections, Analgesics, Osteoporosis, andVaccinations for Years 2003, 2008 & 2012 (includescorresponding Graph/Chart) II-62III. COMPETITIVE LANDSCAPETo order this report:

World Intranasal Drug Delivery Market

http://www.reportlinker.com/p092577/World-Intranasal-Drug-Delivery-Market.html

More market research reports here!

Contacts:Reportlinker.comNicolasUS: (805) 652-2626 or Intl: +1-805-652-2626Email: nbo@reportlinker.com